Niagen Bioscience, Inc. Net Income Loss

• Niagen Bioscience, Inc. showed an increase of +103.3% in Net Income Loss from 2024 to 2025.
• This data is from Niagen Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Niagen Bioscience, Inc.'s Net Income Loss has grown by 947.2%.
• Historical annual values: Fiscal year 2025: $17.38 million | Fiscal year 2024: $8.55 million | Fiscal year 2023: -$4.94 million | Fiscal year 2022: -$16.54 million | Fiscal year 2021: -$27.13 million | Fiscal year 2020: -$19.93 million | Fiscal year 2019: -$32.15 million | Fiscal year 2018: -$33.32 million | Fiscal year 2017: -$11.38 million | Fiscal year 2016: -$2.93 million | Fiscal year 2015: -$2.77 million | Fiscal year 2014: -$5.39 million | Fiscal year 2013: -$4.42 million | Fiscal year 2012: -$11.66 million | Fiscal year 2011: -$7.89 million | Fiscal year 2010: -$2.05 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026